Establishing Vantive
Proposed Kidney Care Separation
We began the journey to establish our chronic kidney care and acute therapies businesses into one standalone company in January 2023. The proposed separation from Baxter will establish Vantive, a new standalone company with an impressive 70 years of experience and a single focus on advancing therapies and services for kidney care and other vital organ support. Until completion of the proposed separation, our Kidney Care group will continue to do business as Baxter.
The energy and excitement our organization has toward building a new kidney and critical care company based on a 70-year legacy of pioneering therapy in this space is truly electrifying. Our new brand is coming to life through our teams’ steadfast commitment to helping patients lead full and meaningful lives in partnership with our healthcare customers. We are eager to continue collaborating with the kidney and critical care communities to help transform care.
Chris Toth, Executive Vice President and Group President, Kidney Care; designated CEO, Proposed Kidney Care Company
Committed to Our Patients and Customers
Vantive will continue to serve as a trusted partner to providers and clinicians, focusing on improving outcomes for the more than one million patients we serve every year around the world. We are driven by the role we play in helping patients and their healthcare teams. Their determination inspires us to continually deliver new and bold technologies that will empower them and help to transform chronic kidney care and acute therapies. While we continue to advance the separation activities, we are still operating as Baxter. As we work to seamlessly separate our businesses, we will provide relevant updates to our patients, customers and other stakeholders.
Read More About Our Journey
Baxter Names Chris Toth CEO of Proposed Kidney Care Spinoff
Baxter Announces Vantive as the Name of Proposed Kidney Care Spinoff
Vantive (Proposed Kidney Care Standalone Company)
~$4.5B in 2023 Revenue
>22,000 Employees*
Vantive will build on Baxter’s nearly 70-year commitment to pioneering therapies for kidney patients and providers across modalities. Products will include peritoneal dialysis devices and solutions; connected technologies like the Sharesource remote patient management system; organ support therapies including continuous renal replacement therapy; and hemodialysis filters and systems.
*Employee count as of as of 12/31/23
Learn more about our Kidney Care business:
Updates for Distributors & Suppliers
Until the proposed separation is complete, Baxter will continue to operate as one organization. Your Baxter contact(s) remain the same. Distributor agreements remain in place. We are committed to continuing to deliver the same level of support you receive today. As we work to seamlessly separate our businesses, we will provide updates to our partners as appropriate.
Updates for Investors
The proposed separation is expected to create value for all of our stakeholders, including Baxter shareholders.